TEE
CTSO icon

Tibra Equities Europe’s Cytosorbents Corp CTSO Stock Holding History

Tibra Equities Europe’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-51,313
Closed -$362K – 135
2018
Q1 		$362K Buy
+51,313
New +$388K 0.06% 157

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Tibra Equities Europe's CTSO Position: Q2 2018 in Review

Tibra Equities Europe sold out of Cytosorbents Corp (CTSO) in Q2 2018, closing a stake of 51,313 shares — an estimated $362K sold.

Tibra Equities Europe first reported a position in CTSO in Q1 2018 and held it in 1 quarter. The position peaked at $362K in Q1 2018. 75 funds tracked by Wall St. Rank hold CTSO as of Q2 2018.

  • Tibra Equities Europe reported no remaining Cytosorbents Corp position as of Q2 2018 after selling out during the quarter.
  • Tibra Equities Europe sold 51,313 Cytosorbents Corp shares in Q2 2018, an estimated $362K.
  • Tibra Equities Europe first reported a position in Cytosorbents Corp in Q1 2018 and held it in 1 quarter.
  • Tibra Equities Europe's Cytosorbents Corp position peaked at $362K in Q1 2018.
  • 75 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2018.

Based on Tibra Equities Europe's 13F filing for Q2 2018, filed 10 Aug 2018.